

Diaceutics PLC
("Diaceutics" or the "Company")

Notice of results
Analyst & investor briefing

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces it will release its interim results for the six months ended 30 June 2020 on Monday, 7 September 2020.

Analyst briefing

The Company will host a ZOOM briefing for analysts which will take place at 9.30am on Monday 7 September 2020. If you would like to register to dial in, please contact Walbrook PR on 020 7933 8780 or email diaceutics@walbrookpr.com.

Investor briefing

The Company will also host a private investor call via ZOOM at 4.45pm on Monday, 7 September 2020. If you would like to register to dial in, please contact Walbrook PR on 020 7933 8780 or email diaceutics@walbrookpr.com.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Walbrook PR

Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny
Michael Johnson (Sales)

+44 (0) 20 7391 8900

Walbrook PR

Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Group, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUNRVRRUUWUAR